

# Efficacy of strontium ranelate versus placebo on the time to fracture healing in osteoporotic men and osteoporotic post-menopausal women

<b>Submission date</b> 28/05/2010	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
<b>Registration date</b> 05/07/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Protocol
<b>Last Edited</b> 21/04/2020	<b>Condition category</b> Musculoskeletal Diseases	<input type="checkbox"/> Statistical analysis plan
		<input checked="" type="checkbox"/> Results
		<input type="checkbox"/> Individual participant data

## Plain English summary of protocol

Not provided at time of registration and not expected to be available in the future

## Contact information

### Type(s)

Scientific

### Contact name

Prof Maria Brandi

### Contact details

University of Florence  
Department of Internal Medicine  
Division of Rheumatology and Metabolic bone Disease  
Viale Pieraccini, 18  
Florence  
Italy  
50139

## Additional identifiers

### EudraCT/CTIS number

2009-014271-41

### IRAS number

### ClinicalTrials.gov number

### Secondary identifying numbers

## Study information

### Scientific Title

A multicentre, prospective, randomised, double-blind, placebo-controlled, international study to assess the effects of 2 g per day of strontium ranelate versus placebo on the time to fracture healing in osteoporotic men and women

### Acronym

The Fracture healing study

### Study objectives

To demonstrate the efficacy of strontium ranelate 2 g versus placebo in accelerating radiological healing of distal radius fractures.

Please note that as of 27/11/2012, Belgium, Russian Federation and Ukraine were added to the countries of recruitment.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Ethics approval was obtained before recruitment of the first participants

### Study design

Randomised double-blind placebo-controlled study

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Hospital

### Study type(s)

Treatment

### Participant information sheet

Not available in web format, please use the contact details below to request a patient information sheet

### Health condition(s) or problem(s) studied

Radius fracture, Osteoporosis

### Interventions

One daily administration of strontium ranelate 2 g or placebo during 24 weeks. There is no visit after the last intake at week-24.

**Intervention Type**

Other

**Phase**

Phase III

**Primary outcome measure**

Time to radiological healing. Radiological evaluation will be performed at baseline, at week 4, 6, 7, 8, 9, 10, 12, 14 and at the last study visit. No radiography will be performed once radiological healing is complete, except at the last study visit.

**Secondary outcome measures**

1. Other radiological evaluations, performed at baseline, at week 4, 6, 7, 8, 9, 10, 12, 14 and at the last study visit. No radiography will be performed once radiological healing is complete, except at the last study visit.
2. Clinical evaluation (including mobility, quality of life, etc), performed at least once every 4 weeks from baseline to week 18 and at the last study visit
3. Safety evaluation, performed at least once every 4 weeks from baseline to week 18 and at the last study visit

**Overall study start date**

01/05/2010

**Completion date**

31/03/2012

**Eligibility****Key inclusion criteria**

1. Osteoporotic men and osteoporotic post-menopausal women
2. Aged superior or equal to 50 years
3. Patient with a fracture of the distal radius (Colles' fracture)

**Participant type(s)**

Patient

**Age group**

Senior

**Sex**

Both

**Target number of participants**

200

**Total final enrolment**

217

**Key exclusion criteria**

1. Fractures not meeting inclusion criteria (including displaced radius fractures)
2. Concomitant treatments likely to interfere with bone metabolism

**Date of first enrolment**

01/05/2010

**Date of final enrolment**

31/03/2012

## **Locations**

**Countries of recruitment**

Belgium

Brazil

Czech Republic

France

Germany

Hungary

Italy

Russian Federation

Ukraine

United Kingdom

**Study participating centre**

University of Florence

Florence

Italy

50139

## **Sponsor information**

**Organisation**

Institut de Recherches Internationales Servier (France)

**Sponsor details**

50 rue Carnot  
Suresnes  
France  
92284

**Sponsor type**  
Industry

**Website**  
<http://www.servier.com/>

**ROR**  
<https://ror.org/034e7c066>

## Funder(s)

**Funder type**  
Industry

**Funder Name**  
Institut de Recherches Internationales Servier (France)

## Results and Publications

### Publication and dissemination plan

Publication plan:

Summary results are published on <https://clinicaltrials.servier.com>.

For interventional Phase III studies ending after the 1st January 2014, the results are/will be published in scientific literature.

### Intention to publish date

### Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from <https://clinicaltrials.servier.com> if a Marketing Authorisation has been granted after 1st January 2014.

### IPD sharing plan summary

Available on request

### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Basic results</a>				No	No
<a href="#">Basic results</a>			21/04/2020	No	No